The European Journal of Health Economics

, Volume 11, Issue 4, pp 405–412 | Cite as

Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain

  • Juan Oliva-Moreno
  • Julio López-Bastida
  • Pedro Serrano-Aguilar
  • Lilisbeth Perestelo-Pérez
Original Paper

Abstract

The aims of this study were to estimate medical expenditures on human immunodeficiency virus (HIV) treatment and to identify significant associated variables. We performed a retrospective multi-centre study in the Canary Islands using a sample of 569 patients recruited at outpatient visits. The study examined demographic and clinical variables, health-related quality of life (HRQOL), and health care resources. Clinical data was obtained from medical records and patient interviews. Several empirical models for identifying the relationship between health care costs and independent variables were developed. The greatest expense came from pharmaceutical expenditure (82.1% of direct costs), while hospital costs only represented 4.6% of total expenditure. The data showed a statistically significant association between health care costs and the CD4 count of the previous year. HRQOL was also a significant variable. Therefore, CD4 cell count can be used to predict health care costs in patients. Policymakers could use this information to help guide their decisions in allocating limited health care resources to HIV treatments.

Keywords

HIV/AIDS Health care costs Health-related quality of life Observational multi-centre study 

References

  1. 1.
    Ancelle-Park, R.A.: Expanded European AIDS case definition. Lancet 341, 441 (1993)CrossRefGoogle Scholar
  2. 2.
    Anis, A.H., Guh, D., Hogg, R.S., et al.: The cost-effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics 18, 393–404 (2000)CrossRefGoogle Scholar
  3. 3.
    Antoñanzas-Villar, F., Anton-Botella, F., Juarez-Castello, C.: The calculation of AIDS costs in Spain by simulation techniques. Med. Clin. (Barc) 104, 568–572 (1995)Google Scholar
  4. 4.
    Basuyau, F., Josset, V., Merle, V., et al.: Case fatality and health care costs in HIV-infected patients: evolution from 1992 to 2000 at Rouen University Hospital, France. Int. J. STD AIDS 15, 679–684 (2004)CrossRefGoogle Scholar
  5. 5.
    Beck, E.J., Mandalia, S., Gaudreault, M., et al.: The cost-effectiveness of highly active antiretroviral therapy. Canada 1991–2001. AIDS 18, 2411–2418 (2004)Google Scholar
  6. 6.
    Beck, E.J., Mandalia, S., Griffith, R., et al.: Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre. Pharmacoeconomics 17, 53–69 (2000)CrossRefGoogle Scholar
  7. 7.
    Beck, E.J., Mandalia, S., Williams, I., et al.: Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996–1997. AIDS 13, 2157–2164 (1999)CrossRefGoogle Scholar
  8. 8.
    Beck, E.J., Miners, A.H., Tolley, K.: The cost of HIV treatment and care. A global review. Pharmacoeconomics 19, 13–39 (2001)CrossRefGoogle Scholar
  9. 9.
    Bernell, S.L., Shinogle, J.A.: The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook. Health Policy 71, 255–264 (2005)CrossRefGoogle Scholar
  10. 10.
    Canary Island Health Programme [online]. http://www.gobiernodecanarias.org/sanidad/scs/1/plansalud/plansalud2004_2008/ppal.htm. Accessed 5 May 2008
  11. 11.
    Castilla, J., De la Fuente, L.: Evolución del número de personas infectadas por el virus de la inmunodeficiencia humana y de los casos de sida en España: 1980–1998. Med. Clin. (Barc) 115, 85–89 (2000)Google Scholar
  12. 12.
    Clark, R.: Sex differences in antiretroviral therapy-associated intolerance and adverse effects. Drug Saf. 28, 1075–1083 (2005)CrossRefGoogle Scholar
  13. 13.
    Conelli, J.E., Philbrick, J.T., Smith, G.R., et al.: Health perceptions of primary care patients and the influence on health care utilization. Med. Care 27, S99–S109 (1989)CrossRefGoogle Scholar
  14. 14.
    Dray-Spira, R., Lert, F., Marimoutou, C., et al.: Socio-economic conditions, health status and employment among persons living with HIV/AIDS in France in 2001. AIDS Care 15, 739–748 (2003)CrossRefGoogle Scholar
  15. 15.
    Fauci, A.S.: The AIDS epidemic. Considerations for the 21st century. N. Engl. J. Med. 341, 1046–1050 (1999)CrossRefGoogle Scholar
  16. 16.
    Flori, Y.A., le Vaillant, M.: Use and cost of antiretrovirals in France 1995–2000: an analysis based on the medical dossier on human immunodeficiency (release 2) database. Pharmacoeconomics 22, 1061–1070 (2004)CrossRefGoogle Scholar
  17. 17.
    Garattini, L., Tediosi, F., Di Cintio, E., et al.: Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care 13, 733–741 (2001)CrossRefGoogle Scholar
  18. 18.
    Goldman, D.P., Bao, Y.: Effective HIV treatment and the employment of HIV(+) adults. Health Serv. Res. 39(6 Pt 1), 1691–1712 (2004)CrossRefGoogle Scholar
  19. 19.
    Greene, W.H.: Econometric analysis, 3rd edn. MacMillan, New York (2000)Google Scholar
  20. 20.
    Hellinger, F.J.: Economic models of antiretroviral therapy: searching for the optimal strategy. Pharmacoeconomics 24, 631–642 (2006)CrossRefGoogle Scholar
  21. 21.
    Hellinger, F.J.: The lifetime cost of treating a person with HIV. JAMA 270, 474–478 (1993)CrossRefGoogle Scholar
  22. 22.
    Idler, E.L., Benyamini, Y.: Self-rated health and mortality: a review of twenty-seven community studies. J. Health Soc. Behav. 38, 21–37 (1997)CrossRefGoogle Scholar
  23. 23.
    ILO (International Labour Organization): HIV/AIDS: a threat to decent work, productivity and development (2000). Document for discussion at the special high—level meeting on HIV/AIDS and the world of work. Geneva, 8 June 2000. SafeWork—Programme on HIV/AIDS. http://www.ilo.org/public/english/protection/trav/aids/publ/threathdecentworkeng.pdf
  24. 24.
    Kahn, J.G., Marseille, E.: Fighting global AIDS: the value of cost-effectiveness analysis. AIDS 14, 2609–2610 (2000)CrossRefGoogle Scholar
  25. 25.
    Kaplan, G., Barell, V., Lusky, A.: Subjective state of health and survival in elderly adults. J Gerontol. 43, S114–S120 (1988)Google Scholar
  26. 26.
    Keiser, P., Nassar, N., Kvanli, M.B., et al.: Long-term impact of highly active antiretroviral therapy on HIV-related health care. J Acquir. Immune Defic. Syndr. 27, 14–19 (2001)Google Scholar
  27. 27.
    King, J.T. Jr., Justice, A.C., Roberts, M.S., et al.: Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med. Decis. Making 23, 9–20 (2003)CrossRefGoogle Scholar
  28. 28.
    Konstam, V., Salem, D., Pouleur, H., et al.: Studies of left ventricular dysfunction investigators. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure: SOLVD investigations. Am. J. Cardiol. 78, 890–895 (1996)CrossRefGoogle Scholar
  29. 29.
    Krentz, H.B., Auld, M.C., Gill, M.J., et al.: The changing direct costs of medical care for patients with HIV/AIDS, 1995–2001. CMAJ 169, 106–110 (2003)Google Scholar
  30. 30.
    Krentz, H.B., Auld, M.C., Gill, M.J.: The high cost of medical care for patients who pesent late (CD4 <200 cells/microL) with HIV infection. HIV Med. 5, 93–98 (2004)CrossRefGoogle Scholar
  31. 31.
    Labeaga, J.M., Oliva, J.: Labour participation of people living with HIV/AIDS. FEDEA Working Paper 2006–2029. www.fedea.es
  32. 32.
    Levy, A.R., James, D., Johnston, K.M., et al.: The direct costs of HIV/AIDS care. Lancet Infect. Dis. 6, 171–177 (2006)CrossRefGoogle Scholar
  33. 33.
    Merito, M., Bonaccorsi, A., Pammolli, F., et al.: Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. Health Policy 74, 304–313 (2005)CrossRefGoogle Scholar
  34. 34.
    Mompo, C., Abbas, I., Santin, M., et al.: Health care resources utilization in HIV-infected patients: creation of a data base and cost results. Gac. Sanit. 14, 39–47 (2000)Google Scholar
  35. 35.
    Oliva J.: Labour participation of Spanish people living with HIV between 2001–2004. Health Econ. Published online 15 April 2009Google Scholar
  36. 36.
    Ojo, K., Delaney, M.: Economic and demographic consequences of AIDS in Namibia: rapid assessment of the costs. Int. J. Health Plann. Manage. 12, 315–326 (1997)CrossRefGoogle Scholar
  37. 37.
    Palella, F.J. Jr., Baker, R.K., Moorman, A.C., et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 43, 27–34 (2006)CrossRefGoogle Scholar
  38. 38.
    Rabkin, J.G., McElhiney, M., Ferrando, S.J., et al.: Predictors of employment of men with HIV/AIDS: a longitudinal study. Psychosom. Med. 66, 72–78 (2004)CrossRefGoogle Scholar
  39. 39.
    Ries, A.L., Kaplan, R.M., Limbreg, T.M., et al.: Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann. Intern. Med. 122, 823–832 (1995)Google Scholar
  40. 40.
    Rodriguez-Artalejo, F., Guallar-Castillon, P., Pascual, C.R., et al.: Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure. Arch. Intern. Med. 165, 1274–1279 (2005)CrossRefGoogle Scholar
  41. 41.
    Schackman, B.R., Gebo, K.A., Walensky, R.P., et al.: The lifetime cost of current human immunodeficiency virus care in the United States. Med. Care 44, 990–997 (2006)CrossRefGoogle Scholar
  42. 42.
    Sendi, P., Palmer, A.J., Gafni, A., et al.: Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 19, 709–713 (2001)CrossRefGoogle Scholar
  43. 43.
    Siu, A.L., Reuben, D.B., Ouslander, J.B., et al.: Using multidimensional health measures in older persons to identify the risk of hospitalization and skilled nursing placement. Qual. Life Res. 2, 253–261 (1993)CrossRefGoogle Scholar
  44. 44.
    SOIKOS: Base de datos de costes sanitarios. SOIKOS, Barcelona (2005)Google Scholar
  45. 45.
    Spanish Ministry of Health and Consumer Affairs: HIV and AIDS epidemiological surveillance in Spain. National Register of AIDS Cases, Madrid (2008)Google Scholar
  46. 46.
    Stoll, M., Claes, C., Schulte, E., et al.: Direct costs for the treatment of HIV infection in a German cohort after the introduction of HAART. Eur. J. Med. Res. 7, 463–471 (2002)Google Scholar
  47. 47.
    Sullivan, M.: The new subjective medicine: taking the patient’s point of view on health care and health. Soc. Sci. Med. 56, 1595–1604 (2003)CrossRefGoogle Scholar
  48. 48.
    The EuroQol Group: EuroQol—a new facility for the measurement of health related quality of life. Health Policy 16, 199–208 (1999)Google Scholar
  49. 49.
    Torti, C., Casari, S., Palvarini, L., et al.: Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy 65, 261–267 (2003)CrossRefGoogle Scholar
  50. 50.
    Tramarin, A., Campostrini, S., Postma, M.J., et al.: A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Pharmacoeconomics 22, 43–53 (2004)CrossRefGoogle Scholar
  51. 51.
    UNAIDS. Report on the global AIDS epidemic, UNAIDS, Geneva (2006)Google Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Juan Oliva-Moreno
    • 1
    • 2
    • 6
  • Julio López-Bastida
    • 4
    • 5
    • 3
  • Pedro Serrano-Aguilar
    • 4
    • 3
  • Lilisbeth Perestelo-Pérez
    • 4
    • 3
  1. 1.Department of Economic Analysis and FinancesUniversity of Castilla la Mancha (UCLM)ToledoSpain
  2. 2.CIBERESP-CIBER in Epidemiology and Public HealthToledoSpain
  3. 3.CIBERESP-CIBER in Epidemiology and Public HealthSanta Cruz de TenerifeSpain
  4. 4.Evaluation and Planning ServiceCanary Islands Health Service (SCS)Santa Cruz de TenerifeSpain
  5. 5.University Hospital Nuestra Señora de la CandelariaCanary Islands Health ServiceSanta Cruz de TenerifeSpain
  6. 6.Facultad de Ciencias Jurídicas y Sociales de Toledo Análisis Económico y Finanzas Cobertizo de San Pedro Mártir s/nToledoEspaña

Personalised recommendations